Page last updated: 2024-12-04

dihydrolipoic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

dihydrolipoic acid: RN given refers to parent cpd without isomeric designation [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

dihydrolipoic acid : A thio-fatty acid that is reduced form of lipoic acid. A potent antioxidant shown to directly destroy superoxide, hydroperoxy and hydroxyl radicals; also has neuroprotective and anti-tumour effects. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

dihydrolipoate : The conjugate base of dihydrolipoic acid. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID421
CHEBI ID18047
SCHEMBL ID19773
MeSH IDM0064201

Synonyms (64)

Synonym
6,8-dimercaptooctanoic acid
6,8-dimercapto-octanoic acid
6,8-bis-sulfanyloctanoic acid
dihydro-lipoic acid
CHEBI:18047
6,8-dihydrothioctic acid
6,8-disulfanyloctanoic acid
dihydro-alpha-lipoic acid
dhla
dihydrolipoicacid
6,8-dimercaptooctanoate
dihydro-alpha-lipoate
6,8-disulfanyloctanoate
6,8-bis-sulfanyloctanoate
octanoic acid, 6,8-dimercapto-
lipoic acid, dihydro-
reduced lipoic acid
usaf xr-12
reduced thioctic acid
dl-dihydro-alpha-6-thioctic acid
thioctic acid, dihydro-
dihydrolipoate
dihydrothioctic acid
462-20-4
dihydrolipoic acid
bdbm16436
d,l-dihydrolipoic acid
6,8-bis(sulfanyl)octanoic acid
7nv2khu5ja ,
ec 610-288-5
unii-7nv2khu5ja
A827012
FT-0687226
gtpl6738
(+/-)-dihydro-.alpha.-lipoic acid
IZFHEQBZOYJLPK-UHFFFAOYSA-N
6,8-bismercaptooctanoic acid
6,8-dimercapto octanoic acid
SCHEMBL19773
dl-a-lipoic acid, dihydro-
mfcd00166974
lipoic acid, reduced, analytical standard
(+/-)-dihydrolipoic acid
dihydro-thiocytic acid
dihydro-dl-alpha-lipoic acid
reduced dl-6,8-thioctic acid
dihydro-a-lipoate
reduced lipoate
dihydro-thioctic acid
dl-dihydro-a-6-thioctic acid
dihydro-a-lipoic acid
dihydro-dl-alpha-lipoate
6,8-dimercapto-octanoate
dihydro-lipoate
d,l-dihydrolipoate
Q5276437
6,8-dimercapto-n-octanoic acid
D4586
(+/-)-6,8-dimercaptooctanoic acid
AS-57050
AKOS037645093
HY-116807
DTXSID50861946
CS-0066565

Research Excerpts

Overview

Dihydrolipoic acid (DHLA) is a constituent of cellular energy metabolism. It cycles between the oxidized and reduced form.

ExcerptReferenceRelevance
"Dihydrolipoic acid (DHLA) is a constituent of cellular energy metabolism, where it cycles between the oxidized and reduced form. "( Dihydrolipoic acid maintains ubiquinone in the antioxidant active form by two-electron reduction of ubiquinone and one-electron reduction of ubisemiquinone.
Gille, L; Kozlov, AV; Nohl, H; Staniek, K, 1999
)
3.19

Effects

Dihydrolipoic acid (DHLA) has been reported as a strong antioxidant and exhibits anti-inflammatory properties in various diseases. The direct relevance between DHLA and depression is yet unknown.

ExcerptReferenceRelevance
"Dihydrolipoic acid (DHLA) has been reported as a strong antioxidant and exhibits anti-inflammatory properties in various diseases, albeit the direct relevance between DHLA and depression is yet unknown."( Dihydrolipoic acid protects against lipopolysaccharide-induced behavioral deficits and neuroinflammation via regulation of Nrf2/HO-1/NLRP3 signaling in rat.
Bian, H; Huang, J; Liang, L; Wang, G; Wang, H; Wei, Y; Xiao, L; Zheng, Y, 2020
)
2.72
"Dihydrolipoic acid (DHLA) has been found to stimulate the Ca(2+)-induced mitochondrial permeability transition (MPT) in rat liver mitochondria (RLM) [Biochem. "( Reactive oxygen species are involved in the stimulation of the mitochondrial permeability transition by dihydrolipoate.
Gille, L; Kruglov, AG; Morkunaite-Haimi, S; Nohl, H; Saris, NE; Stolze, K; Teplova, VV, 2003
)
1.76

Toxicity

ExcerptReferenceRelevance
" Used as dietary supplement alpha-lipoic acid was demonstrated to be safe for living organisms even when administered at high doses."( Safety of oral alpha-lipoic acid treatment in pregnant women: a retrospective observational study.
Colannino, G; Monastra, G; Parente, E; Picconi, O, 2017
)
0.46
" Maternal safety was assessed by monitoring for adverse reactions, physical and clinical examination, including a morbidity assessment."( Safety of oral alpha-lipoic acid treatment in pregnant women: a retrospective observational study.
Colannino, G; Monastra, G; Parente, E; Picconi, O, 2017
)
0.46
" No adverse effect was noticed in mothers or newborns."( Safety of oral alpha-lipoic acid treatment in pregnant women: a retrospective observational study.
Colannino, G; Monastra, G; Parente, E; Picconi, O, 2017
)
0.46

Bioavailability

ExcerptReferenceRelevance
" It is widely accepted that diabetes impairs endothelial nitric oxide synthase (eNOS) activity and increases the production of ROS, thus resulting in diminished NO bioavailability and increased oxidative stress."( Alpha-lipoic acid: molecular mechanisms and therapeutic potential in diabetes.
Ghibu, S; Muresan, A; Rochette, L; Vergely, C, 2015
)
0.42

Dosage Studied

ExcerptRelevanceReference
" These results provide important information in terms of dosage safety and biocompatibility of DHLA to facilitate its further use as a precursor for biomaterial preparation."( Impact of dihydrolipoic acid on mouse embryonic stem cells and related regulatory mechanisms.
Chan, WH; Chang, WH; Houng, WL; Hsieh, JT; Lee, CH; Li, PW; Lin, CA; Shen, JL; Yeh, HI, 2013
)
0.79
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (3)

RoleDescription
neuroprotective agentAny compound that can be used for the treatment of neurodegenerative disorders.
antioxidantA substance that opposes oxidation or inhibits reactions brought about by dioxygen or peroxides.
human metaboliteAny mammalian metabolite produced during a metabolic reaction in humans (Homo sapiens).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
thio-fatty acidAny fatty acid having at least one SH substituent.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (11)

PathwayProteinsCompounds
Glycine and Serine Metabolism2452
Ammonia Recycling1227
Dimethylglycine Dehydrogenase Deficiency2452
Dihydropyrimidine Dehydrogenase Deficiency (DHPD)2452
Sarcosinemia2452
Non-Ketotic Hyperglycinemia2452
Hyperglycinemia, Non-Ketotic2452
3-Phosphoglycerate Dehydrogenase Deficiency2452
Arsenate Detoxification716
Metabolic Epileptic Disorders2589
Selenium micronutrient network095

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Aldo-keto reductase family 1 member B1Homo sapiens (human)Ki0.95000.01903.41939.3000AID1797503
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (15)

Processvia Protein(s)Taxonomy
retinoid metabolic processAldo-keto reductase family 1 member B1Homo sapiens (human)
epithelial cell maturationAldo-keto reductase family 1 member B1Homo sapiens (human)
renal water homeostasisAldo-keto reductase family 1 member B1Homo sapiens (human)
carbohydrate metabolic processAldo-keto reductase family 1 member B1Homo sapiens (human)
prostaglandin metabolic processAldo-keto reductase family 1 member B1Homo sapiens (human)
C21-steroid hormone biosynthetic processAldo-keto reductase family 1 member B1Homo sapiens (human)
L-ascorbic acid biosynthetic processAldo-keto reductase family 1 member B1Homo sapiens (human)
regulation of urine volumeAldo-keto reductase family 1 member B1Homo sapiens (human)
retinol metabolic processAldo-keto reductase family 1 member B1Homo sapiens (human)
negative regulation of apoptotic processAldo-keto reductase family 1 member B1Homo sapiens (human)
daunorubicin metabolic processAldo-keto reductase family 1 member B1Homo sapiens (human)
doxorubicin metabolic processAldo-keto reductase family 1 member B1Homo sapiens (human)
fructose biosynthetic processAldo-keto reductase family 1 member B1Homo sapiens (human)
cellular hyperosmotic salinity responseAldo-keto reductase family 1 member B1Homo sapiens (human)
metanephric collecting duct developmentAldo-keto reductase family 1 member B1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (10)

Processvia Protein(s)Taxonomy
retinal dehydrogenase activityAldo-keto reductase family 1 member B1Homo sapiens (human)
aldose reductase (NADPH) activityAldo-keto reductase family 1 member B1Homo sapiens (human)
protein bindingAldo-keto reductase family 1 member B1Homo sapiens (human)
electron transfer activityAldo-keto reductase family 1 member B1Homo sapiens (human)
prostaglandin H2 endoperoxidase reductase activityAldo-keto reductase family 1 member B1Homo sapiens (human)
glyceraldehyde oxidoreductase activityAldo-keto reductase family 1 member B1Homo sapiens (human)
allyl-alcohol dehydrogenase activityAldo-keto reductase family 1 member B1Homo sapiens (human)
L-glucuronate reductase activityAldo-keto reductase family 1 member B1Homo sapiens (human)
glycerol dehydrogenase [NADP+] activityAldo-keto reductase family 1 member B1Homo sapiens (human)
all-trans-retinol dehydrogenase (NADP+) activityAldo-keto reductase family 1 member B1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (4)

Processvia Protein(s)Taxonomy
extracellular spaceAldo-keto reductase family 1 member B1Homo sapiens (human)
nucleoplasmAldo-keto reductase family 1 member B1Homo sapiens (human)
cytosolAldo-keto reductase family 1 member B1Homo sapiens (human)
extracellular exosomeAldo-keto reductase family 1 member B1Homo sapiens (human)
cytosolAldo-keto reductase family 1 member B1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (1)

Assay IDTitleYearJournalArticle
AID1797503Enzyme Inhibition Assay from Article 10.1016/j.bioorg.2006.09.004: \\Structural and thermodynamic studies of simple aldose reductase-inhibitor complexes.\\2006Bioorganic chemistry, Dec, Volume: 34, Issue:6
Structural and thermodynamic studies of simple aldose reductase-inhibitor complexes.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (237)

TimeframeStudies, This Drug (%)All Drugs %
pre-199015 (6.33)18.7374
1990's75 (31.65)18.2507
2000's70 (29.54)29.6817
2010's66 (27.85)24.3611
2020's11 (4.64)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 37.54

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index37.54 (24.57)
Research Supply Index5.50 (2.92)
Research Growth Index5.08 (4.65)
Search Engine Demand Index61.46 (26.88)
Search Engine Supply Index2.36 (0.95)

This Compound (37.54)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews11 (4.53%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other232 (95.47%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]